Seqens commits to US market with multi-million dollar investment in R&D
A redeveloped R&D facility will enhance Seqens' capabilities in developing and producing APIs and active delivery systems development
Just 3 months after Seqens was merged with Wavelength Pharmaceuticals to create a significantly larger and diversified CDMO the company has made a bold move to increase its US presence with a multimillion-dollar investment in new R&D facilities at its laboratory in Devens, Massachusetts.
The investment will enable the specialist manufacturer of APIs and pharmaceutical intermediates to increase its R&D capability and productivity of APIs and active delivery systems (lipids and polymers) development which, in turn, will bolster its global R&D network.
Furthermore, the transaction is set to strengthen the company’s US foothold — which also includes a sales office and CDMO operation in nearby Newburyport — and demonstrates the company's commitment to broadening its reach in the US market.
In addition to the re-development of its Devens laboratory, Seqens is investing significantly across the enterprise in its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, HPAPIs and biocatalysts.
Seqens' President Pierre Luzeau said the combination of Wavelength's technologies, products and expertise will enable the company to "accelerate the projects launched in recent months" and support customers worldwide in the development of their projects.
The merger with Wavelength broadens Seqens' global reach by providing production facilities in Israel and India, and sales offices in Europe and the US.
The expansion projection is expected to be completed by the beginning of 2023.
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.